Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319433 | 0.94 | AURKA (1.00) | AURKAAURKB | |
| SCHEMBL4306936 | 0.93 | AURKA (1.00) | AURKAAURKB | |
| SCHEMBL4313570 | 0.91 | AURKA (0.83) | AURKAAURKB | |
| SCHEMBL4314921 | 0.91 | AURKA (0.83) | AURKAAURKB | |
| SCHEMBL4310019 | 0.90 | AURKA (0.82) | AURKAAURKB | |
| SCHEMBL4306872 | 0.90 | AURKB (1.00) | AURKAAURKB | |
| SCHEMBL4311958 | 0.89 | AURKA (0.81) | AURKAAURKB | |
| SCHEMBL4312314 | 0.89 | AURKA (0.80) | AURKAAURKB | |
| SCHEMBL4310031 | 0.89 | AURKA (0.84) | AURKAAURKB | |
| SCHEMBL4310684 | 0.89 | AURKA (0.80) | AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962830-B1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7605266-B2 | Azaindole inhibitors of Aurora kinases | SMITHKLINE BEECHAM (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605266-B2 | Azaindole inhibitors of Aurora kinases | SMITHKLINE BEECHAM (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605266-B2 | Azaindole inhibitors of Aurora kinases | SMITHKLINE BEECHAM (US) | 2009-10-20 | — | — | US | disclosed |
| US-7495102-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495102-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495102-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | GLAXOSMITHKLINE LLC | 2008-12-11 | — | — | US | disclosed |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | GLAXOSMITHKLINE LLC | 2008-12-11 | — | — | US | disclosed |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | GLAXOSMITHKLINE LLC | 2008-12-11 | — | — | US | disclosed |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-7282588-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282588-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282588-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2007-06-28 | — | — | US | disclosed |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2007-06-28 | — | — | US | disclosed |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885 |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885 |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885 |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.